53 results about "Soft tissue sarcoma" patented technology

The present invention relates to a pharmaceutical cocktail, in particular, effective amounts of gemcitabine, in combination with effective amounts of docetaxel and angiogenesis inhibitor, especially a vascular endothelial growth factor (VEGF) inhibitor, such as bevacizumab for the treatment of cancer, in particular sarcoma, especially soft tissue sarcoma. Pharmaceutical compositions and methods of treating cancer, including sarcoma, especially soft tissue sarcoma (prolonging the patient's life, eliminating the tumor, improving the patient's quality of life, shrinking the tumor, prolonging survival and/or preventing the tumor's metastases) are additional aspects of the present invention.

The invention relates to a melphalan freeze-dried powder injection and a preparing method thereof. The prepared melphalan freeze-dried powder injection is used for treating multiple myeloma, oophoroma, polycythemia vera, local malignant melanoma and soft tissue sarcoma. The melphalan freeze-dried powder injection contains melphalan, utilizes the mixed solvent composed of the tert-butyl alcohol and the injection water in the preparation process, wherein the concentration of the melphalan in the mixed solvents is 10-25 mg/ml; and the volume ratio of the solvents is: 5-50% of tert-butyl alcohol and the balance of injection water. The preparation process comprises the following steps: measuring tert-butyl alcohol, adding injection water, mixing evenly, cooling to 2-15 DEG C, heat preserving, adding melphalan, stirring and dripping 0.5 mol hydrochloric acid to dissolve, filtering, filling, plugging, disking, freeze-drying, pressing plug, out box, tying and packing after quality test qualification.

The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treat with a composition of this invention in hopes of reducing the risk of recurrence.

The invention discloses a cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy and an application thereof. The medicine is characterized by comprising the following components: the liquid medicine in every 100 milliliters contains 2-10ml of absolute ethyl alcohol, 40-50mg of cis-platinum complexes and 90-98ml of sterile water. The medicine is mainly used for local injection of tumors or intravesical therapy of chest, abdomen, pericardial cavity malignant effusion or aerosol inhalation therapy of lung tumors, and is suitable for the therapy of various solid tumors such as lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, mammary cancer, retroperitoneal tumor or retroperitoneal lymph node metastasis, cardia cancer, gastrointestinal malignant cancer, soft tissue sarcoma, glioma and head and neck neoplasm and the medicine-resistant or medicine-sensitive tumor therapy with chest, abdomen, pericardial cavity malignant effusion.

The invention belongs to the field of biological medicines and relates to an application of a GPS2 gene in preparation of drugs for prognosis, diagnosis or prevention and treatment of soft tissue tumor. The GPS2 gene is in low expression in soft-tissue sarcoma such as liposarcoma, and proliferation of the liposarcoma can be promoted by inhibiting the expression of the GPS2 gene. The expression of the GPS2 gene has obvious relevance with prognosis of the liposarcoma, which shows that the GPS2 gene can be used for clinical pathological diagnosis of patients with liposarcoma. The GPS2 gene can be used as a tumor-suppressing gene in the liposarcoma, and can be used as a possible prognostic marker and a therapeutic molecule of the liposarcoma.

This invention relates to the use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (hereinafter also referred to as HECNU) for treatment of pancreatic carcinomas, soft tissue sarcomas, testicular tumors, lymphomas, thymomas, Wilms' tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastases, tumors in the head and neck area and mammary carcinomas.

The invention belongs to the technical field of traditional Chinese medicine, and specifically discloses a Chinese medicinal composition for treating malignant soft tissue neoplasm. The Chinese medicinal composition for treating malignant soft tissue neoplasm is prepared from bulk pharmaceuticals including astragalus, coix seed, fried large-head atractylodes rhizome, Yunnan indian buead, dried orange peel, pinellia tuber, rhizoma bolbostemmae, Chinese angelica, turmeric root-tuber, flos muse, silktree albizzia bark, common selfheal fruit-spike, dandelion, philippine violet herb, ternate buttercup root, spreading hedyotis herb, barbed skullcap herb, indian iphigenia bulb, stiff silkworm, toad, glabrous greenbrier rhizome, umbellate pore fungus, areca nut, lychee seed, cowherb seed, semen pharbitidis and bitter orange. The Chinese medicinal composition for treating malignant soft tissue neoplasm provided by the invention is a pure Chinese medicinal preparation, has a remarkable curative effect according to multiple years of clinical application, and is an ideal medicament for preventing and treating malignant soft tissue neoplasm.

Described herein are methods and compositions that can be used for diagnosis and treatment of soft tissue sarcoma cancer phenotypes and soft tissue sarcoma cancer-associated diseases. Also described herein are methods that can be used to identify modulators of soft tissue sarcoma cancer.

The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.

The invention discloses a lung metastasis prediction method for patients with limb soft tissue sarcoma, and the method comprises the steps: S1, carrying out the feature extraction of all to-be-testedobjects through employing a standard shooting value of a PET image, wherein the features comprises an SUV feature and a texture feature; s2, carrying out feature extraction on all tested clinical information by using a one-hot encoding method; and S3, performing feature contribution degree sorting on all the features by using a random forest algorithm, fusing the high contribution degree features,and constructing a lung metastasis prediction model of the patient with the limb soft tissue sarcoma by using a BP neural network. The lung metastasis prediction method can predict the lung metastasis condition of patients with limb soft tissue sarcoma more accurately by using fewer patient characteristics.

The invention provides a soft tissue sarcoma grade judgment method based on machine learning. The method comprises the steps of carrying out the typical feature extraction of a soft tissue sarcoma image, obtaining the typical features of the soft tissue sarcoma images of all patients in a sampling sample, forming a sample data set, carrying out the preprocessing of the sample data set, dividing the preprocessed sample data set into a test set and a training set, based on the generated training set, constructing machine learning models by adopting different machine learning algorithms respectively and training the machine learning models, and substituting the generated test set into the plurality of constructed machine learning models respectively for calculation to obtain a predicted valuecalculated by each machine learning model, calculating the difference between the predicted value and a true value, and selecting the machine learning model with the minimum difference as a soft tissue sarcoma grade judgment model. Excellent experience of doctors and experts can be accumulated so as to be conveniently copied to other small cities and small hospitals to be popularized and used, the diagnosis accuracy is improved, and then the cure rate of patients is increased.

The invention relates to a novel anti-tumor epirubicin compound being an epirubicin hydrochloride v-type compound, wherein the novel compound is easy to prepare and has advantages of less hygroscopicity, improved storage stability, good promotion of drug quality control and the like. The novel anti-tumor epirubicin compound is used for application in treatment and preventive drugs for treatment ofthe malignant lymphomam, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia, and brain glioma, treatment of the superficial bladder cancer and carcinoma in situ by the intravesical administration, and prevention of recurrence after transurethral resection and the like.

The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.

The invention relates to a gene probe for alveolar soft part sarcoma and application of a gene probe kit. Clonal fragments selected and used by the gene probe are RP11-634L10, RP11-51H16 and RP11-475F12 combination as well as CTD-2311N12, RP11-416B14, CTD-2522M13, CTD-2312C1 and CTD-2248C21 combination respectively. According to the gene probe, the defects of an influence on prognostic and postoperative treatment and the like due to a tedious and time-consuming RT-PCR (reverse transcription-polymerase chain reaction) and cell karyotype analysis method, limitation of RT-PCR application by RNA degradation and numerous other factors, and inaccurate diagnosis are overcome; the gene probe is high in accuracy, specificity and success rate, strong in fluorescent signal and easy and convenient to operate, and can be applied to paraffin sections; the specimen detection range is extended, a novel method for accurately, reliably, simply and conveniently diagnosing the alveolar soft part sarcoma is built, and a precedent for detecting the alveolar soft part sarcoma by FISH (fluorescence in situ hybridization) is created.

The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.

The present invention relates to the use of anti-PD-1 antibodies and/or antigen-binding fragments thereof in the treatment of malignancies. The present invention relates to the use of anti-PD-1 antibodies and/or antigen-binding fragments thereof in the treatment of sarcoma, preferably in the treatment of vacuolar soft tissue sarcoma, angiosarcoma and undifferentiated polymorphic sarcoma, and the use of anti-PD-1 antibodies and/or antigen-binding fragments thereof in the treatment of lymphoma.

The invention discloses a rabbit anti-human TRK protein monoclonal antibody, can specifically recognize the TRK and/or TRK fusion protein expressed by cells, has stable performance and high titer, hasno cross-reaction with other proteins in the cell, and has certain medical basic research value. The invention also relates to the use of the above monoclonal antibody for the preparation of immunohistochemical detection tools for detecting TRK and/or TRK fusion protein. The application adopts an immunohistochemical method to detect TRK and/or TRK protein of tumor cells including lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colorectal carcinoma, soft tissue sarcoma, salivary gland, infant fibrosarcoma, appendix cancer, breast cancer, cholangiocarcinoma, pancreatic cancer, and the like. The monoclonal antibody provides a powerful scientific reference for the treatment of TRK kinase inhibitors, effectively reduces the cost of treatment, and has important application value.

A method for applying cold atmospheric plasma treatment to target tissue comprising the steps of treating a patient with a pharmaceutical for suppressing apolipoprotein E genes, selecting through a graphical user interface a particular soft tissue sarcoma cell line associated with target tissue, retrieving, with said computing device, settings data associated with said selected soft tissue sarcoma cell line from a database of cell line data and associated settings data in a storage, and applying, with said computing device, said retrieved settings data to a cold atmospheric plasma system.

The invention belongs to the field of molecular biology, and particularly relates to a sarcoma radiotherapy resistance-related diagnostic marker and application. According to application of IF18B as asarcoma biomarker, the IF18B is highly expressed in sarcoma tissue, and tumor cell radiotherapy sensitivity can be improved by inhibiting kinesin family member 18B (KIF18B) expression. According to asarcoma detection product, the sarcoma detection product includes a reagent for detecting KIF18B expression, and is a product used for sarcoma diagnosis, radiotherapy means therapeutic effect evaluation and prognosis judgment. According to the diagnostic marker, genes significantly differential in carcinoma and para-carcinoma tissues in all sarcoma subtypes are widely screened, and are intersected with differentially expressed genes (DEGs) in carcinoma and para-carcinoma tissues of soft tissue sarcoma in a The Cancer Genome Atlas (TCGA) database, and it is the first time to discover that thegenes can be used as targets in all subtypes of sarcomas so as to improve huge differences of treatment schemes for patients with different subtypes of sarcomas at present; and the radiotherapy resistance-related gene KIF18B is obtained by further screening, which proves that the radiotherapy sensitivity of sarcoma cells can be enhanced by inhibiting the KIF18B, and the KIF18B can be used as a specific target for sarcoma radiotherapy. According to the diagnostic marker, by taking the KIF18 as the biomarker and with a targeting therapy, a new thought is provided for sarcoma treatment, and detection indexes are also provided for radiotherapy means therapeutic effect evaluation and prognosis judgment, and the diagnostic marker has important clinical application value.